Efficient Implementation of DPYD Testing Using an Institutional Genetics Data Repository

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity genetic variants in DPYD, which encodes the enzyme that metabolizes fluoropyrimidine, leading to higher systemic drug exposure and increased risk of severe and fatal toxicity. Many European countries recommend DPD/DPYD screening prior to fluoropyrimidine treatment and there are guidelines from Clinical Pharmacogenetics Implementation Consortium (CPIC) that recommend safe fluoropyrimidine starting doses in known DPYD carriers. However, DPYD testing is not recommended by the FDA or clinical oncology practice guidelines, which has led to minimal testing in the United States. One of the main reasons for the lack of clinical uptake is the cost of testing large numbers of patients to find the relatively uncommon (~5%) DPYD carriers. A potential solution that has not been explored, to our knowledge, is to use existing research-only genetic data to identify suspected carriers of actionable genotypes who should undergo confirmatory testing prior to treatment. This talk will summarize the evidence of the clinical benefit of pre-treatment DPYD testing and the reasons that testing is rarely conducted in the US. I will then describe ongoing work to use an institutional genetic data repository for ultra-efficient DPYD implementation at the University of Michigan Rogel Cancer Center. Finally, I will describe our efforts to get oncology clinical guidelines and the FDA to recommend pre-treatment DPYD testing and give the audience a simple way to support our effort. 

Learning Objectives:

1. Identify the five actionable DPYD variants that increase risk of fluoropyrimidine toxicity

2. Describe the main reasons that pre-treatment DPYD testing is not conducted in the United States

3. Recognize the benefits of using existing institutional genetic data for efficient pharmacogenetic implementation


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
OCT 27, 2021 6:00 AM PDT
C.E. CREDITS
OCT 27, 2021 6:00 AM PDT
Date: October 27, 2021 Time: 6:00 AM PDT, 9:00 AM EDT Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
DEC 09, 2021 6:00 AM PST
C.E. CREDITS
DEC 09, 2021 6:00 AM PST
Date: December 9, 2021 Time: 6:00am (PDT), 9:00 am (EDT) As the number of biotherapeutic candidates in development is increasing, the requirements of analytical tools to understand the molec...
Loading Comments...
Show Resources